Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
174900
vs
K
KOSPI 200
Over the past 12 months, AbClon Inc has underperformed KOSPI 200, delivering a return of -19% compared to KOSPI 200's +57% growth.
Stocks Performance
174900 vs KOSPI 200
Performance Gap
174900 vs KOSPI 200
Performance By Year
174900 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AbClon Inc
Glance View
AbClon is a biotechnology company that discovers and develops antibody-based medicines. Its work centers on finding antibodies that can become drugs, especially for cancer and other serious diseases, and then turning those candidates into treatments that can be tested and sold through partners or later by the company itself. The company also works on antibody tools used in diagnostics and research, so it is not only a drug developer but also a supplier of antibody know-how. Its customers are mainly pharmaceutical partners, research groups, and healthcare-related users that need antibody candidates, development support, or future therapies. AbClon makes money through collaboration deals, licensing arrangements, and eventually product sales if its drug candidates reach the market. What makes AbClon different is that it sits at the early end of the biopharma value chain. Instead of mass-manufacturing drugs, it focuses on the harder first step: discovering and engineering antibodies that can be developed into medicines or diagnostic products. That gives it a business model built around scientific development, partnerships, and long-term product pipelines rather than routine industrial sales.